Sutureless Valve in Repeated Aortic Valve Replacement: Results from an International Prospective Registry

• Published in: Innovations (Philadelphia, Pa.) p. 1556984521999323
• Main Authors: Glauber, Mattia, Kent, William D T, Asimakopoulos, George, Troise, Giovanni, Padrò, Josep Maria, Royse, Alistair, Marnette, Jean-Marc, Noirhomme, Philippe, Baghai, Max, Lewis, Michael, Di Bacco, Lorenzo, Solinas, Marco, Miceli, Antonio
• Format: Journal Article
• Language: English
• Published: United States 01.05.2021
• Subjects: redo surgery; AVR; sutureless
• ISSN: 1559-0879
• DOI: 10.1177/1556984521999323

To report early and midterm results registry of patients undergoing repeated aortic valve replacement (RAVR) with sutureless prostheses from an international prospective registry (SURE-AVR). Between March 2011 and June 2019, 69 patients underwent RAVR with self-expandable sutureless aortic bioprostheses at 22 international cardiac centers. Overall mortality was 2.9% with a predicted logistic EuroSCORE II of 10.7%. Indications for RAVR were structural valve dysfunction (84.1%) and infective prosthetic endocarditis (15.9%) and were performed in patients with previously implanted bioprostheses (79.7%), mechanical valves (15.9%), and transcatheter valves (4.3%). Minimally invasive approach was performed in 15.9% of patients. Rate of stroke was 1.4% and rate of early valve-related reintervention was 1.4%. Overall survival rate at 1 and 5 years was 97% and 91%, respectively. No major paravalvular leak occurred. Rate of pacemaker implantation was 5.8% and 0.9% per patient-year early and at follow-up, respectively. The mean transvalvular gradient at 1-year and 5-year follow-up was 10.5 mm Hg and 11.5 mm Hg with a median effective orifice area of 1.8 cm and 1.8 cm , respectively. RAVR with sutureless valves is a safe and effective approach and provides excellent clinical and hemodynamic results up to 5 years.